Allergan Inc. Earnings: Margins Expand Again, Profit Rises
S&P 500 (NYSE:SPY) component Allergan Inc. (NYSE:AGN) reported its results for the fourth quarter. Allergan is a global specialty health care company. It discovers, develops, and commercializes innovative pharmaceuticals, biologics, and medical devices, as well as over-the-counter products.
Investing Insights: Will the iPad 3 Be the Next Catalyst for Apple’s Stock?
Allergan Earnings Cheat Sheet for the Fourth Quarter
Results: Net income for the drug manufacturer rose to $279.8 million (90 cents per share) vs. $263.1 million (87 cents per share) in the same quarter a year earlier. This marks a rise of 6.3% from the year earlier quarter.
Revenue: Rose 7.1% to $1.4 billion from the year earlier quarter.
Actual vs. Wall St. Expectations: Allergan Inc. reported adjusted net income of $1 per share. By that measure, the company beat the mean estimate of 99 cents per share. Analysts were expecting revenue of $1.41 billion.
Quoting Management: “We are very pleased with our fourth quarter and full year growth of sales and profits, as well as the significant regulatory approvals received in 2010 and 2011,” said David E.I. Pyott, Allergan’s Chairman of the Board, President and Chief Executive Officer. “In 2012, we look forward to building on the momentum gained from the regulatory approvals, and increased investment in R&D to further strengthen our pipeline.”
The company has now topped analyst estimates for the last four quarters. It beat the mark by 2 cents in the third quarter, by one cent in the second quarter, and by 3 cents in the first quarter.
Revenue has risen the past four quarters. Revenue increased 9.9% to $1.33 billion in the third quarter. The figure rose 13.6% in the second quarter from the year earlier and climbed 10.1% in the first quarter from the year-ago quarter.
Looking Forward: The outlook for the company’s next quarter results is favorable. The average estimate for the first quarter of the next fiscal year has reached 91 cents, up from 90 cents seven days ago. For the fiscal year, the average estimate has been unchanged at $3.64 a share.
(Company fundamentals provided by Xignite Financials. Earnings estimates provided by Zacks)
Don’t Miss These Additional Hot Earnings Stories:
To contact the reporter on this story: Derek Hoffman at firstname.lastname@example.org
To contact the editor responsible for this story: Damien Hoffman at email@example.com